 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | 4SCAR-CD44v6 T Cell Therapy / SZGIMI
New P1/2 trial: 4SCAR-CD44v6 T Cell Therapy Targeting Cancer (clinicaltrials.gov) - Jun 11, 2020
P1/2, N=100, Recruiting, Sponsor: Shenzhen Geno-Immune Medical Institute